Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) to discuss second quarter 2023 financial results in conference call and webcast. Management will address novel therapies for glaucoma, corneal disorders, and retinal diseases. Investors can participate by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) and entering Conference ID 7935742.

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2023 financial results after the market close on Wednesday, August 2, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 2, 2023.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230712447925/en/

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

What is the purpose of the conference call and webcast?

The purpose is to discuss Glaukos Corporation's second quarter 2023 financial results and management's insights on novel therapies for glaucoma, corneal disorders, and retinal diseases.

When will the second quarter 2023 financial results be released?

The results will be released after the market close on Wednesday, August 2, 2023.

How can investors participate in the conference call?

Investors can participate by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) and entering Conference ID 7935742.

Where can the live webcast be accessed?

The live webcast will be available on the company’s website at http://investors.glaukos.com.

Will there be a replay of the conference call?

Yes, a replay will be archived on the company’s website following completion of the call.